The NHS will save £7 billion by the end of 2023 thanks to a new five-year agreement, which ensures the NHS can continue to be one of the fastest health systems in the world to roll out innovative medicines. The Voluntary Scheme for Branded Medicines Pricing and Access (VPAS), was introduced in 2019 to keep the branded medicine bill affordable by capping the growth of sales. Thanks to the scheme, thousands of NHS patients have benefitted from new treatments for the most common cancers, to cutting edge gene therapy for ultra-rare conditions. |